Remotely controlled drug release based on iron oxide nanoparticles for specific therapy of cancer.
Chemotherapy has been widely used in clinic and usually causes serious side effects. To improve therapeutic effect, it is really necessary to realize local drug release and specific therapy. In this work, we demonstrate Azo (4,4-azobis (4-cyanovaleric acid))-functionalized multifunctional nanoparticles to realize near-infrared (NIR) laser-responsive drug release and combined chemo-photothermal cancer therapy. Doxorubicin (DOX) was attached to magnetic nanoparticles via a thermal-cleavable Azo linker, which could decompose while the temperature reach ∼43°C. The Azo-functioned Fe3O4NPs also showed good capability as a contrast for T2-weighted magnetic resonance (MR) images in vivo. After intravenous injection, the Fe3O4-Azo NPs could targeted accumulate in the tumor. Once exposed to NIR irradiation, Fe3O4nanoparticles (NPs) absorb NIR light to generate heat rapidly, resulting in the tumor specific DOX release and remarkable tumor growth inhibition effect. The Azo-functionalized Fe3O4NPs with multifunction of in vivo imaging and combined therapy present a potential for tumor diagnosis treatment.
Affiliated Hospital of Jiangsu University, Zhenjiang 212001, PR China.
Lin
L
Wu
College of Pharmaceutical Sciences, Jiangsu University, Zhenjiang 212013, PR China.
Ling
L
Chen
College of Pharmaceutical Sciences, Jiangsu University, Zhenjiang 212013, PR China.
Fei
F
Liu
College of Pharmaceutical Sciences, Jiangsu University, Zhenjiang 212013, PR China.
Xueyong
X
Qi
College of Pharmaceutical Sciences, Jiangsu University, Zhenjiang 212013, PR China. Electronic address: geyanru@ujs.edu.cn.
Yanru
Y
Ge
College of Pharmaceutical Sciences, Jiangsu University, Zhenjiang 212013, PR China. Electronic address: jsdx.shensong@163.com.
Song
S
Shen
D045744:Cell Line, Tumor; D003692:Delayed-Action Preparations / Q000737:chemistry*; D004317:Doxorubicin / Q000737:chemistry*; D004337:Drug Carriers / Q000737:chemistry*; D065546:Drug Liberation; D005290:Ferric Compounds / Q000737:chemistry*; D006367:HeLa Cells; D006801:Humans; D053758:Nanoparticles / Q000737:chemistry*
D003692:Delayed-Action Preparations; D004337:Drug Carriers; D005290:Ferric Compounds; C000499:ferric oxide; D004317:Doxorubicin
Combined therapy; Doxorubicin; Magnetic iron oxide; NIR sensitive release; Photothermal therapy